446 related articles for article (PubMed ID: 27908880)
1. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
Leong SR; Sukumaran S; Hristopoulos M; Totpal K; Stainton S; Lu E; Wong A; Tam L; Newman R; Vuillemenot BR; Ellerman D; Gu C; Mathieu M; Dennis MS; Nguyen A; Zheng B; Zhang C; Lee G; Chu YW; Prell RA; Lin K; Laing ST; Polson AG
Blood; 2017 Feb; 129(5):609-618. PubMed ID: 27908880
[TBL] [Abstract][Full Text] [Related]
2. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
[TBL] [Abstract][Full Text] [Related]
3. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
Friedrich M; Henn A; Raum T; Bajtus M; Matthes K; Hendrich L; Wahl J; Hoffmann P; Kischel R; Kvesic M; Slootstra JW; Baeuerle PA; Kufer P; Rattel B
Mol Cancer Ther; 2014 Jun; 13(6):1549-57. PubMed ID: 24674885
[TBL] [Abstract][Full Text] [Related]
4. An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.
Zheng B; Yu SF; Del Rosario G; Leong SR; Lee GY; Vij R; Chiu C; Liang WC; Wu Y; Chalouni C; Sadowsky J; Clark V; Hendricks A; Poon KA; Chu W; Pillow T; Schutten MM; Flygare J; Polson AG
Clin Cancer Res; 2019 Feb; 25(4):1358-1368. PubMed ID: 29959143
[TBL] [Abstract][Full Text] [Related]
5. CD33 directed bispecific antibodies in acute myeloid leukemia.
Clark MC; Stein A
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101224. PubMed ID: 33279180
[TBL] [Abstract][Full Text] [Related]
6. Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties.
Ovacik AM; Li J; Lemper M; Danilenko D; Stagg N; Mathieu M; Ellerman D; Gupta V; Kalia N; Nguy T; Plaks V; David Johnson C; Wang W; Brumm J; Fine B; Junttila T; Lin K; Carter PJ; Prabhu S; Spiess C; Kamath AV
MAbs; 2019; 11(2):422-433. PubMed ID: 30550367
[TBL] [Abstract][Full Text] [Related]
7. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW
Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753
[TBL] [Abstract][Full Text] [Related]
8. An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.
Yeung YA; Krishnamoorthy V; Dettling D; Sommer C; Poulsen K; Ni I; Pham A; Chen W; Liao-Chan S; Lindquist K; Chin SM; Chunyk AG; Hu W; Sasu B; Chaparro-Riggers J; Djuretic I
Mol Ther; 2020 Mar; 28(3):889-900. PubMed ID: 31981494
[TBL] [Abstract][Full Text] [Related]
9. MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis.
van Loo PF; Hangalapura BN; Thordardottir S; Gibbins JD; Veninga H; Hendriks LJA; Kramer A; Roovers RC; Leenders M; de Kruif J; Doornbos RP; Sirulnik A; Throsby M; Logtenberg T; Dolstra H; Bakker ABH
Expert Opin Biol Ther; 2019 Jul; 19(7):721-733. PubMed ID: 31286786
[No Abstract] [Full Text] [Related]
10. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
[TBL] [Abstract][Full Text] [Related]
11. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells.
Arndt C; von Bonin M; Cartellieri M; Feldmann A; Koristka S; Michalk I; Stamova S; Bornhäuser M; Schmitz M; Ehninger G; Bachmann M
Leukemia; 2013 Apr; 27(4):964-7. PubMed ID: 23325142
[No Abstract] [Full Text] [Related]
12. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Sun LL; Ellerman D; Mathieu M; Hristopoulos M; Chen X; Li Y; Yan X; Clark R; Reyes A; Stefanich E; Mai E; Young J; Johnson C; Huseni M; Wang X; Chen Y; Wang P; Wang H; Dybdal N; Chu YW; Chiorazzi N; Scheer JM; Junttila T; Totpal K; Dennis MS; Ebens AJ
Sci Transl Med; 2015 May; 7(287):287ra70. PubMed ID: 25972002
[TBL] [Abstract][Full Text] [Related]
13. Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.
Lu H; Zhou Q; Deshmukh V; Phull H; Ma J; Tardif V; Naik RR; Bouvard C; Zhang Y; Choi S; Lawson BR; Zhu S; Kim CH; Schultz PG
Angew Chem Int Ed Engl; 2014 Sep; 53(37):9841-5. PubMed ID: 25056598
[TBL] [Abstract][Full Text] [Related]
14. Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager.
Eissenberg LG; Ritchey JK; Rettig MP; Patel DA; Vij K; Gao F; Smith V; Han TH; DiPersio JF
PLoS One; 2024; 19(5):e0300174. PubMed ID: 38696390
[TBL] [Abstract][Full Text] [Related]
15. Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release.
Lee E; Lee S; Park S; Son YG; Yoo J; Koh Y; Shin DY; Lim Y; Won J
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37848261
[TBL] [Abstract][Full Text] [Related]
16. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
[TBL] [Abstract][Full Text] [Related]
17. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
Zugmaier G; Klinger M; Schmidt M; Subklewe M
Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
Bonnevaux H; Guerif S; Albrecht J; Jouannot E; De Gallier T; Beil C; Lange C; Leuschner WD; Schneider M; Lemoine C; Caron A; Amara C; Barrière C; Siavellis J; Bardet V; Luna E; Agrawal P; Drake DR; Rao E; Wonerow P; Carrez C; Blanc V; Hsu K; Wiederschain D; Fraenkel PG; Virone-Oddos A
Oncoimmunology; 2021; 10(1):1945803. PubMed ID: 34484869
[TBL] [Abstract][Full Text] [Related]
19. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
20. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.
Nair-Gupta P; Diem M; Reeves D; Wang W; Schulingkamp R; Sproesser K; Mattson B; Heidrich B; Mendonça M; Joseph J; Sendecki J; Foulk B; Chu G; Fink D; Jiao Q; Wu SJ; Packman K; Elsayed Y; Attar R; Gaudet F
Blood Adv; 2020 Mar; 4(5):906-919. PubMed ID: 32150609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
